Among significant research news last week, US biotech Allakos reported that it was dropping development of its urticaria ...

The European Commission (EC) has authorized the combination of ViiV Healthcare’s Vocabria (cabotegravir long-acting ...

Shares of US drugmaker Vertex Pharmaceuticals jumped 8.4% to $475.00 in after-hours trading yesterday after it announced that ...

Rentschler Biopharma is moving away from cell and gene therapy as part of a strategic realignment, opting to focus more on ...

Novartis’ (NOVN: VX) results show the firm humming along nicely in 2024, with sales driven by continued strong performance ...

Blackstone (NYSE: BX), the world’s largest alternative asset manager, is expanding its presence in the life sciences sector ...

The European Medicines Agency’s (EMA) human medicines committee (CHMP) recommended four novel medicines for approval at its ...

US pharma major AbbVie has posted financial results for the fourth quarter and full year ended December 31, 2024, that pleased investors and sending the firm’s shares up 7.8% to $189.19 by mid-morning ...

Clinical-stage USA-based drug developer Inhibikase Therapeutics saw its shares tumble more than 31% to $1.92, after is ...

Japanese drugmaker Daiichi Sankyo has appointed Hiroyuki Okuzawa to succeed Sunao Manabe, as chief executive (CEO), effective April 1, 2025.

Privately-held Swiss dermatology company Galderma today announced today results from its new Phase IIIb RELAX clinical trial ...

US clinical-stage biotech CARGO Therapeutics’ shares plummeted more than 75% to $3.23 yesterday, after it announced that it ...